Acute Non-traumatic Myelopathies

  • K. Venkatraman
  • N. Thamil Pavai
  • R. Lakshmi Narasimhan


Acute and chronic disorders of the spinal cord produce a number of distinctive syndromes which relate to its special anatomical and physiological features. These unique clinical syndromes usually indicate a specific underlying etiology.


  1. 1.
    Gregory G, Jose B. Spinal cord anatomy, localization, and overview of spinal cord syndromes. Continuum (Minneap Minn). 2008;14:11–35.Google Scholar
  2. 2.
    Adams RD, Victor M, Ropper AH. Principles of neurology. New York: McGraw-Hill; 2009.Google Scholar
  3. 3.
    Hauser SL, Ropper AH. Diseases of the spinal cord. In: Fauci AS, et al., editors. Harrison’s textbook of internal medicine. 17th ed. New York: McGraw-Hill; 2008. p. 2588–95.Google Scholar
  4. 4.
    Barnes G, Benjamin S, Bowen JD, Transverse Myelitis Consortium Working Group, et al. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59:500–5.Google Scholar
  5. 5.
    Banwell B, Dale RC. Understanding risk of relapse and risk of disability after childhood transverse myelitis. Neurology. 2015;84:332–4.CrossRefGoogle Scholar
  6. 6.
    Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2011;77:2128–34.CrossRefGoogle Scholar
  7. 7.
    Bruna J, Martínez-Yélamos S, Martínez-Yélamos A, et al. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler. 2006;12:169–73.CrossRefGoogle Scholar
  8. 8.
    Kimbrough DJ, Mealy MA, Alexandra Simpson RN, Michael Levy MS. Predictors of recurrence following an initial episode of transverse myelitis. Neurol Neuroimmunol Neuroinflamm. 2014;1:e4.CrossRefGoogle Scholar
  9. 9.
    deSeze J, Stojkovic T, Breteau G, et al. Acute myelopathies: clinical, lab and outcome profiles in 79 cases. Brain. 2001;124:1509–21.CrossRefGoogle Scholar
  10. 10.
    Scalfari A, Neuhaus A, Degenhardt A. The natural history of multiple sclerosis, a geographically based study: relapses and long-term disability. Brain. 2010;133:1914–29.CrossRefGoogle Scholar
  11. 11.
    Filippi M, Rocca MA, Ciccarelli O. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292–303.CrossRefGoogle Scholar
  12. 12.
    Mandler RN, Dencoff JD, Midani F. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic’s neuromyelitis optica. Brain. 2001;124:493–8.CrossRefGoogle Scholar
  13. 13.
    Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev. 2000;4:CD001331. Scholar
  14. 14.
    Burton JM, O’Connor PW, Hohol M, et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2009;3:CD006921. Scholar
  15. 15.
    Wingerchuk DM, Banwell B, Bennett JL. International consensus diagnostic criteria for neuromyelitisoptica spectrum disorders. Neurology. 2015;85:177–89.CrossRefGoogle Scholar
  16. 16.
    Melamed E, Levy M, Waters PJ. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e134.CrossRefGoogle Scholar
  17. 17.
    Kitley J, Leite MI, Nakashima I. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitisoptica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834–184.CrossRefGoogle Scholar
  18. 18.
    Collongues N, Marignier R, Ze’phir H, Papeix C. Long-term follow-up of neuromyelitisoptica with a pediatric onset. Neurology. 2010;75:1084–8.CrossRefGoogle Scholar
  19. 19.
    Sandson TA, Friedman TH. Spinal cord infarction: report of 8 cases and review of literature. Medicine. 1989;68:282–92.CrossRefGoogle Scholar
  20. 20.
    Benaventte O, Barnett HJM. Spinal cord ischaemia. In: Barnett HJM, Mohr JP, Stern BM, Yatsu FM, editors. Stroke: pathophysiology, diagnosis and management. 3rd ed. Philadelphia: Churchill Livingstone; 1998. p. 751–65.Google Scholar
  21. 21.
    Herrick MK, Mills PE Jr. Infarction of spinal cord: two cases of selective gray matter involvement secondary to asymptomatic aortic disease. Arch Neurol. 1971;24:228–41.CrossRefGoogle Scholar
  22. 22.
    Szilagyi DE, Hageman JH, Smith RF, et al. Spinal cord damage in surgery of the abdominal aorta. Surgery. 1978;83:38–56.PubMedGoogle Scholar
  23. 23.
    Rabinstein AA. Vascular myelopathies. Continuum (Minneap Minn). 2015;21(1):67–83.Google Scholar
  24. 24.
    Cheshire WP, Santos CC, Massey EW, et al. Spinal cord infarction: etiology and outcome. Neurology. 1996;47:321–30.CrossRefGoogle Scholar
  25. 25.
    Hughes JT, Brownell B. Spinal cord ischaemia due to arteriosclerosis. Arch Neurol. 1966;15:189–202.CrossRefGoogle Scholar
  26. 26.
    Kim RC, Smith HR, Henbest ML, et al. Nonhemorrhagic venous infarction of the spinal cord. Ann Neurol. 1984;15:379–85.CrossRefGoogle Scholar
  27. 27.
    Haddad MC, Aabed al-Thagafi MY, Djurberg H. MRI of spinal cord and vertebral body infarction. Am J Neuroradiol. 1992;13:145–54.Google Scholar
  28. 28.
    Kuker W, Weller M, Klose U. Diffusion-weighted MRI of spinal cord infarction—high resolution imaging and time course of diffusion abnormality. J Neurol. 2004;251:818–24.CrossRefGoogle Scholar
  29. 29.
    Sacco RL, Adams R, Albers G, American Heart Association, American Stroke Association Council on Stroke, Council on Cardiovascular Radiology and Intervention, American Academy of Neurology, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577–617.CrossRefGoogle Scholar
  30. 30.
    Chang CWJ, Donovan DJ, Liem LK. Surfers’ myelopathy. Neurology. 2012;79:2171–6.CrossRefGoogle Scholar
  31. 31.
    Lyons JL. Myelopathy associated with microorganisms. Continuum (Minneap Minn). 2015;21(1):100–20.Google Scholar
  32. 32.
    Darouiche RO, Hamill RJ, Greenberg SB, et al. Bacterial spinal epidural abscess: review of 43 cases and literature survey. Medicine. 1992;71:369–85.CrossRefGoogle Scholar
  33. 33.
    Gregory RO, Seto CK, Wortley GC, et al. Acute lumbar disc pain: navigating evaluation and treatment choices. Am Fam Physician. 2008;78:835–42.PubMedGoogle Scholar
  34. 34.
    Jarvik JG, Hollingworth W, Martin B, et al. Rapid MRI versus radiographs for patients with low back pain: a randomized controlled trial. JAMA. 2003;289:2810–8.CrossRefGoogle Scholar
  35. 35.
    Kostuik JP, Harrington I, Alexander D, et al. Cauda equine syndrome and lumbar disc herniation. J Bone Joint Surg Am. 1986;68:386–91.CrossRefGoogle Scholar
  36. 36.
    Goodman BP. Metabolic and toxic myelopathies. Continuum (Minneap Minn). 2015;21(1):427–40.Google Scholar
  37. 37.
    Tan DYL, Tsou IYY, Chee TSG. Differentiation of malignant vertebral collapse from osteo-porotic and other benign causes using magnetic resonance imaging. Ann Acad Med Singap. 2002;31:8–14.PubMedGoogle Scholar
  38. 38.
    Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol. 1998;16:1613–24.CrossRefGoogle Scholar
  39. 39.
    Loblaw DA, Lapierre N, Perry J, Members of the Neuro-Oncology Disease Site Group, et al. Malignant extradural spinal cord compression: diagnosis and management. Evidence summary report 9–9. Toronto: Cancer care Ontario; 2007.Google Scholar
  40. 40.
    Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomized trial. Lancet. 2005;366:643–8.CrossRefGoogle Scholar
  41. 41.
    Chamberlain MC. Neoplastic myelopathies. Continuum (Minneap Minn). 2015;21(1):132–45.Google Scholar
  42. 42.
    Mohapatra BN, Mohanty CB. Treatment of tuberculosis WHO guidelines 2010.
  43. 43.
    Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62.CrossRefGoogle Scholar
  44. 44.
    Rasouli MR, Mirkoohi M, Vaccaro AR. Spinal tuberculosis: diagnosis and management. Asian Spine J. 2012;6(4):294–308.CrossRefGoogle Scholar
  45. 45.
    Kannan B, Kannan A, Saravanan C, Venkatesan EP. First case report of caissons disease with pneumobilia. Neurol India. 2014;62:690–1.CrossRefGoogle Scholar
  46. 46.
    Hallenbeck JM, Bove AA, Elliott DH. Mechanisms underlying spinal cord damage in decompression sickness. Neurology. 1975;25:308–316A.CrossRefGoogle Scholar
  47. 47.
    Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008;28(1):105–20.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Authors and Affiliations

  • K. Venkatraman
    • 1
  • N. Thamil Pavai
    • 1
  • R. Lakshmi Narasimhan
    • 1
  1. 1.Institute of NeurologyMadras Medical CollegeChennaiIndia

Personalised recommendations